Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;33(2 Suppl 2):S31-6.
doi: 10.12788/j.sder.0066.

Tumor Necrosis Factor Inhibitors in Psoriasis: An Update

Affiliations

Tumor Necrosis Factor Inhibitors in Psoriasis: An Update

Francisco A Kerdel et al. Semin Cutan Med Surg. .

Abstract

Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.

Keywords: Immunogenicity; TNF; psoriasis treatment; tumor necrosis factor inhibitors.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

Feedback